Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors.

T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res (2009) 2.26

Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol (2013) 1.26

Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer. Invest New Drugs (2008) 0.82

Prognostic significance of deregulated dicer expression in breast cancer. PLoS One (2013) 0.80

Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Res Treat (2001) 0.77

Role of hormonal risk factors in HER2-positive breast carcinomas. Br J Cancer (2003) 0.75

HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis. Oncotarget (2016) 0.75

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68

Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med (1981) 7.53

Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer (1996) 4.46

Results of a breast-cancer-surgery trial compared with observational data from routine practice. Lancet (1996) 3.78

Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med (1993) 3.54

P53 expression in breast cancer. Int J Cancer (1988) 3.51

Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med (1977) 3.45

Updated Kiel classification for lymphomas. Lancet (1988) 3.25

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol (2008) 2.75

Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer (1982) 2.71

A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature (1987) 2.60

Lack of effect of pregnancy on outcome of melanoma. For The World Health Organisation Melanoma Programme. Lancet (1991) 2.58

Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst (2001) 2.57

Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst (1995) 2.52

Stage I melanoma of the limbs: assessment of prognosis by levels of invasion and maximum thickness. Tumori (1978) 2.46

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab (2000) 2.43

Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet (2001) 2.40

The FHIT gene 3p14.2 is abnormal in lung cancer. Cell (1996) 2.36

Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest (1996) 2.31

Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1,973 patients. Eur J Cancer (1995) 2.30

Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer (1995) 2.28

Breast cancer patients treated without axillary surgery: clinical implications and biologic analysis. Ann Surg (2000) 2.27

Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst (1990) 2.25

Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol (1997) 2.19

Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med (1988) 2.15

Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol (1999) 2.11

Informed versus randomised consent to clinical trials. Lancet (1995) 2.07

The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst (1994) 2.06

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (2015) 2.05

Comparison of Halsted mastectomy with quadrantectomy, axillary dissection, and radiotherapy in early breast cancer: long-term results. Eur J Cancer Clin Oncol (1986) 2.05

Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer (1987) 1.99

Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res (1998) 1.96

High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene (1989) 1.94

Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med (2000) 1.93

Gastrointestinal symptoms in patients with asthma. Arch Dis Child (2000) 1.82

Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol (1994) 1.80

Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. J Natl Cancer Inst (1997) 1.79

A novel non-heme iron-binding ferritin related to the DNA-binding proteins of the Dps family in Listeria innocua. J Biol Chem (1997) 1.77

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol (1996) 1.74

Ten year results of a randomised trial comparing two conservative treatment strategies for small size breast cancer. Eur J Cancer (1998) 1.68

Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res (1991) 1.65

Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci (2002) 1.65

ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol (1998) 1.64

Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet (2003) 1.62

Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol (2008) 1.62

Results of adjuvant interferon study in WHO melanoma programme. Lancet (1994) 1.62

Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial. Gut (2001) 1.61

Generation of monoclonal antibodies reacting with normal and cancer cells of human breast. Cancer Res (1983) 1.60

A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res (1996) 1.60

Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer (1991) 1.58

Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest (1993) 1.57

Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. J Clin Oncol (1996) 1.55

Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas. Br J Cancer (1988) 1.55

Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol (1997) 1.55

Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). Ann Oncol (2005) 1.54

Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol (1991) 1.54

Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene (2012) 1.53

Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg (1991) 1.52

Adequacy of margins of resection in gastrectomy for cancer. Ann Surg (1982) 1.52

Laparoscopy and laparotomy combined with bone marrow biopsy in staging Hodgkin's disease. Br Med J (1975) 1.52

A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer (2000) 1.52

Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene (1992) 1.51

Primary non-Hodgkin's lymphomas of the female breast. Cancer (1992) 1.50

Risk of internal mammary lymph node metastases and its relevance on prognosis of breast cancer patients. Ann Surg (1983) 1.50

Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res (1992) 1.50

Are surgical adjuvant trials altering the course of breast cancer? Semin Oncol (1978) 1.49

Thromboembolic risk in atrial flutter. The FLASIEC (FLutter Atriale Società Italiana di Ecografia Cardiovascolare) multicentre study. Eur Heart J (2001) 1.48

Distribution of axillary node metastases by level of invasion. An analysis of 539 cases. Cancer (1987) 1.48

Clinical diagnosis and therapy of cutaneous melanoma in situ. Cancer (1996) 1.43

Effect of imatinib on haematopoietic recovery following idarubicin exposure. Leukemia (2003) 1.43

Phase II study of intensive CEV (carboplatin, epirubicin and VP-16) plus G-CSF (granulocyte-colony stimulating factor) in extensive small cell lung cancer. Eur J Cancer (1995) 1.42

Extent of metastatic axillary involvement in 1446 cases of breast cancer. Eur J Surg Oncol (1990) 1.40

Acral-lentiginous naevus of plantar skin. Histopathology (1995) 1.39

Distinct morphophenotypic features of chronic B-cell leukaemias identified with CD1c and CD23 antibodies. Eur J Haematol (1991) 1.39

Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res (1997) 1.39

Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer (2001) 1.36

Viral particles in cervical condylomatous lesions. Tumori (1978) 1.36

Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol (2011) 1.36

Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions. Cancer Res (1995) 1.34

Formation of the 67-kDa laminin receptor by acylation of the precursor. J Cell Biochem (1998) 1.34

The 67-kDa laminin receptor originated from a ribosomal protein that acquired a dual function during evolution. Mol Biol Evol (1998) 1.33